Related Experiment Video
Updated: May 7, 2026
06:03
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
2.2K
Bleomycin induced flagellate erythema: Revisiting a unique complication
Ahitagni Biswas1, Pritee B Chaudhari, Punit Sharma
1Department of Radiotherapy and Oncology, All India Institute of Medical Sciences, New Delhi, India.
Journal of Cancer Research and Therapeutics
|October 16, 2013
Summary
Flagellate dermatitis, a rare side effect of bleomycin chemotherapy, is becoming less common. Prompt recognition and management of this skin toxicity are crucial for patients with Hodgkin
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Bleomycin is an antineoplastic agent used in chemotherapy regimens.
- Flagellate dermatitis is a rare but distinct adverse reaction to bleomycin.
- The incidence of bleomycin-induced flagellate dermatitis is decreasing due to reduced bleomycin usage.
Observation:
- A case of a 22-year-old Indian male with Hodgkin's lymphoma (Ann Arbor stage IIBEX) presented with flagellate dermatitis.
- The patient developed the rash after the first cycle of ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) chemotherapy.
- The presentation posed a diagnostic challenge, highlighting the need for clinical awareness.
Findings:
- Early identification and management of bleomycin-induced flagellate dermatitis are essential to minimize patient morbidity.
- Discontinuation of bleomycin is recommended in cases of severe rash.
- In most Hodgkin's lymphoma cases, omitting bleomycin does not negatively impact treatment outcomes.
Implications:
- Awareness of flagellate dermatitis is critical for clinicians managing patients on bleomycin-containing chemotherapy.
- Prompt dermatological intervention can prevent severe complications and improve patient quality of life.
- Treatment protocols for Hodgkin's lymphoma may be adjusted by omitting bleomycin without compromising efficacy.
More Related Videos
Related Concept Videos
01:17Chronic Bowel Disorders: Introduction
908
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
908
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
4.0K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
4.0K
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
205
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
205
01:15Antifungal Agents
132
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
132
01:21Cytotoxic Edema: Pathophysiology
31
Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous...
31
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
1.5K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.5K